Physician profile
David Cos
NPI 1265591242
$17,002.79
in general payments reported to CMS, 2019-2025
74 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,614 · 2020: $2,516 · 2021: $3,328 · 2022: $3,431 · 2023: $3,406 · 2024: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,113.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,092.28 | 2019-2024 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,609.31 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $903.14 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $859.90 | 2019-2023 | Farxiga, Breztri |
| Lilly USA, LLC | $743.96 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $736.31 | 2019-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $718.20 | 2019-2023 | Jardiance, Jentadueto Xr |
| Amarin Pharma, INC. | $647.46 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $572.75 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $507.99 | 2019-2023 | Trintellix |
| Astellas Pharma US INC | $469.64 | 2019-2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $466.59 | 2019-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $455.06 | 2019-2022 | |
| Dexcom, INC. | $432.10 | 2019-2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $405.37 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.